President of Lilly Oncology Announces Resignation
Johnson's decision was driven by personal and family considerations.
Lilly acquired ImClone Systems in 2008, the largest acquisition in Lilly's history. ImClone broadened the Lilly Oncology portfolio and strengthened its oncology pipeline and biotech capabilities. At the time of the acquisition, Johnson was the CEO of ImClone, and he was then brought on to lead Lilly's oncology business.
"Given his previous post at ImClone, John has played a key role leading the integration efforts since Lilly's acquisition," said Lilly chairman, president and CEO
About Lilly Oncology
For more than four decades, Lilly Oncology, a division of
About
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
C-LLY
SOURCE
News Provided by Acquire Media